Pfizer Inc. has a rare 3-year tariff exemption and margin defense amid global price parity risks. Click here to read an ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Pfizer's stock has started to turn higher, but it is still down massively; is now the time to jump aboard?

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer’s stake in ViiV Healthcare will be taken over by Shiongi, another minority shareholder in the HIV medicines company.

The New York powerhouse has agreed to surrender its 11.7% interest in the HIV-focused company for $1.875 billion. Under terms ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer is acquiring a pharma company that has multiple GLP-1 drugs in development. The deal may cost the company up to $7.3 billion, which is a move Pfizer can afford to make given its strong ...

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...